Lobe Sciences Ltd.
Lobe Sciences Ltd. (LOBE.CN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lobe.cn · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lobe Sciences Ltd.You LOBE.CN | $22M | N/A | — | — |
 AI/ML Innovations Inc. AIML.CN | $8M | N/A | — | -$0.03 |
 Avant Brands Inc. AVNT.TO | $7M | N/A | — | -$0.88 |
 Ayurcann Holdings Corp. AYUR.CN | $2M | N/A | — | -$0.02 |
 Blueberries Medical Corp. BBM.CN | $5M | N/A | — | -$0.00 |
 CLS Holdings USA, Inc. CLSH.CN | $8M | N/A | — | -$0.05 |
 Crescita Therapeutics Inc. CTX.TO | $15M | N/A | — | -$0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lobe Sciences Ltd. (LOBE.CN) measures how much investors pay for each dollar of the company's trailing earnings. LOBE.CN's current PE ratio of N/A is calculated by dividing its stock price of $0.12 by its TTM earnings per share of —.
Frequently asked questions
LOBE.CN pe ratio · 6 questionsLOBE.CN's current PE ratio is N/A as of 2026-06-10, based on a stock price of $0.12 and TTM EPS of —. Data sourced from Financial Modeling Prep via LOBE.CN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lobe Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10